Comments: US HB6832 | 2021-2022 | 117th Congress
Bill Title: To amend the Federal Food, Drug, and Cosmetic Act and the Defense Production Act of 1950 to prohibit the Federal Government from limiting State access to key therapies, such as monoclonal antibodies, and from prioritizing Federal contracts over State contracts relating to purchasing supplies to combat the COVID-19 pandemic.
Spectrum: Partisan Bill (Republican 7-0)
Status: (Introduced - Dead) 2022-02-28 - Referred to the Subcommittee on Health. [HB6832 Detail]
Text: Latest bill text (Introduced) [PDF]
Spectrum: Partisan Bill (Republican 7-0)
Status: (Introduced - Dead) 2022-02-28 - Referred to the Subcommittee on Health. [HB6832 Detail]
Text: Latest bill text (Introduced) [PDF]
PolitiCorps Conversations
Start PolitiCorps DebateTitle | PolitiCorps | Access | Comments | Views | Last Post |
---|---|---|---|---|---|
There are no visible public or private PolitiCorps discussions concerning the 2021 US Congress HB6832 at this time. |